Imagine if we could read a child's health blueprint before they are even born. By looking at how the immune system, gut bacteria, and environment interact in the womb and early childhood, we can spot the early warning signs of future allergies or asthma. It is like finding the root cause of a leak in a house before the walls actually start crumbling.
Current medical treatments for immune diseases are reactive and occur after the disease has manifested. There is a lack of precise data on how prenatal and early-life exposures create permanent health risks.
A collaborative data science platform and multi-omics analytical pipelines for intersecting multiple clinical cohorts and biobanks.
If you are a drug discovery firm dealing with high failure rates in asthma treatments — this project developed a data science platform that identifies specific immune maturation mediators. This allows for the creation of targeted therapies based on early-life imprinting.
If you are a probiotic manufacturer dealing with generic product offerings — this project developed insights into how the gut microbiome and metabolism impact life-course health. This enables the design of personalized nutrition for disease prevention.
If you are a diagnostic lab dealing with late-stage disease detection — this project developed a pilot clinical study for personalized disease prevention. This provides the basis for screening tools that target the immune system in the most vulnerable period of life.
Based on available project data, no pricing or cost structures for commercial implementation are provided.
The project uses large population studies and a collaborative data science platform, suggesting the underlying data can scale, though industrial production methods are not detailed.
Based on available project data, specific IP or licensing terms are not mentioned in the summary.
The project integrates multiple cohorts and existing biobanks into a collaborative data science platform for multi-omics studies.
The project period runs from 2023-01-01 to 2028-12-31.
The consortium is heavily academic, with 9 universities and 1 research institute, but it includes 2 SMEs, bringing the industry ratio to 17%. This structure suggests a strong focus on fundamental discovery and data generation, with a small but present bridge to commercial application through the SMEs across 9 countries.
Contact TURUN YLIOPISTO in Finland for partnership inquiries.
Contact us to track the progress of the pilot clinical study for personalized prevention.
